<?xml version='1.0' encoding='utf-8'?>
<document id="27829538"><sentence text="Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females."><entity charOffset="72-82" id="DDI-PubMed.27829538.s1.e0" text="mirabegron" /><entity charOffset="87-98" id="DDI-PubMed.27829538.s1.e1" text="tolterodine" /><pair ddi="false" e1="DDI-PubMed.27829538.s1.e0" e2="DDI-PubMed.27829538.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27829538.s1.e0" e2="DDI-PubMed.27829538.s1.e1" /></sentence><sentence text="Mirabegron, the first selective β3-adrenoceptor agonist for the treatment of overactive bladder (OAB), inhibits cytochrome P450 isozyme CYP2D6"><entity charOffset="0-10" id="DDI-PubMed.27829538.s2.e0" text="Mirabegron" /></sentence><sentence text=" This study was performed in Japanese healthy postmenopausal female volunteers to assess any pharmacokinetic drug interaction between mirabegron and tolterodine, another OAB drug and a sensitive substrate of CYP2D6"><entity charOffset="134-144" id="DDI-PubMed.27829538.s3.e0" text="mirabegron" /><entity charOffset="149-160" id="DDI-PubMed.27829538.s3.e1" text="tolterodine" /><pair ddi="false" e1="DDI-PubMed.27829538.s3.e0" e2="DDI-PubMed.27829538.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27829538.s3.e0" e2="DDI-PubMed.27829538.s3.e1" /></sentence><sentence text=" Tolterodine 4 mg was orally administered from Days 1-7 and co-administered with mirabegron 50 mg from Days 8-14"><entity charOffset="1-12" id="DDI-PubMed.27829538.s4.e0" text="Tolterodine" /><entity charOffset="81-91" id="DDI-PubMed.27829538.s4.e1" text="mirabegron" /><pair ddi="false" e1="DDI-PubMed.27829538.s4.e0" e2="DDI-PubMed.27829538.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27829538.s4.e0" e2="DDI-PubMed.27829538.s4.e1" /></sentence><sentence text=" Mirabegron 50 mg increased maximum concentration (Cmax) and area under the concentration-time curve from zero to 24 h after dosing (AUC24h) of tolterodine by 2"><entity charOffset="1-11" id="DDI-PubMed.27829538.s5.e0" text="Mirabegron" /><entity charOffset="144-155" id="DDI-PubMed.27829538.s5.e1" text="tolterodine" /><pair ddi="false" e1="DDI-PubMed.27829538.s5.e0" e2="DDI-PubMed.27829538.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27829538.s5.e0" e2="DDI-PubMed.27829538.s5.e1" /></sentence><sentence text="06-fold (90% confidence interval [CI] 1" /><sentence text="81, 2" /><sentence text="34) and 1" /><sentence text="86-fold (90% CI 1" /><sentence text="60, 2" /><sentence text="16), respectively, and increased Cmax and AUC24h of the metabolite 5-hydroxymethyl tolterodine by 1"><entity charOffset="67-94" id="DDI-PubMed.27829538.s11.e0" text="5-hydroxymethyl tolterodine" /></sentence><sentence text="36-fold (90% CI 1" /><sentence text="26, 1" /><sentence text="47) and 1" /><sentence text="25-fold (90% CI 1" /><sentence text="15, 1" /><sentence text="37), respectively" /><sentence text=" This suggested a weak pharmacokinetic drug interaction between mirabegron and tolterodine"><entity charOffset="64-74" id="DDI-PubMed.27829538.s18.e0" text="mirabegron" /><entity charOffset="79-90" id="DDI-PubMed.27829538.s18.e1" text="tolterodine" /><pair ddi="false" e1="DDI-PubMed.27829538.s18.e0" e2="DDI-PubMed.27829538.s18.e0" /><pair ddi="false" e1="DDI-PubMed.27829538.s18.e0" e2="DDI-PubMed.27829538.s18.e1" /></sentence><sentence text=" Mean change from baseline of Fridericia's QT correction formula (ΔQTcF) was slightly higher on Day 14 than on Day 7" /><sentence text=" No subject had QTcF &gt;480 msec or ΔQTcF &gt;60 msec" /><sentence text=" All the treatment-emergent adverse events were mild" /><sentence text=" Mirabegron 50 mg was considered to be safe and well tolerated when coadministered with tolterodine 4 mg in healthy postmenopausal female volunteers"><entity charOffset="1-11" id="DDI-PubMed.27829538.s22.e0" text="Mirabegron" /><entity charOffset="88-99" id="DDI-PubMed.27829538.s22.e1" text="tolterodine" /><pair ddi="false" e1="DDI-PubMed.27829538.s22.e0" e2="DDI-PubMed.27829538.s22.e0" /><pair ddi="false" e1="DDI-PubMed.27829538.s22.e0" e2="DDI-PubMed.27829538.s22.e1" /></sentence><sentence text="" /></document>